Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2012, Pages

  Gordon, Patrick A ^a   Winer, John B ^b   Hoogendijk, Jessica E ^c   Choy, Ernest HS ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

APHERESIS; DERMATOMYOSITIS; HUMAN; LEUKAPHERESIS; META ANALYSIS; PLASMAPHERESIS; POLYMYOSITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BLOOD COMPONENT REMOVAL; DERMATOMYOSITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; PLASMA EXCHANGE; POLYMYOSITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866772312     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003643.pub4     Document Type: Review

References (45)

1. Bunch TW, Worthington JW, Combs JJ, Ilstrup MS, Engel AG. Azathioprine with prednisone for polymyositis. Annals of Internal Medicine 1980;92(3):365-9. [PUBMED: 6986827]x-wiley/crsRef/3261667
2. Coyle K, Pokrovnichka A, French K, Joe G, Shrader J, Swan L, et al. A randomized, double-blind, placebo-controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis and Rheumatism 2008;58(Suppl):Abstract No: 2058. x-wiley/crsRef/3261669
3. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New England Journal of Medicine 1993;329(27):1993-2000. [PUBMED: 8247075]x-wiley/crsRef/3261671
4. Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. New England Journal of Medicine 1992;326(21):1380-4. [PUBMED: 1472183]x-wiley/crsRef/3261673
5. Miller J, Walsh Y, Saminaden S, Lecky BRF, Winer JB. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. Journal of the Neurological Sciences 2002;199(Suppl 1):S53. x-wiley/crsRef/3261675
6. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Annals of Neurology 2011;70(3):427-36. [PUBMED: 21688301]x-wiley/crsRef/3261677
7. NCT00112385. A pilot study of etanercept in dermatomyositis. http://clinicaltrials.gov/ct2/show/results/NCT00112385 (accessed 5 July 2012). x-wiley/crsRef/3261678
8. Takada K, Bookbinder S, Furie R, Oddis C, Mojcik C, Bombara M, et al. A pilot study of eculizumab in patients with dermatomyositis. Arthritis and Rheumatism 2002;46 (Suppl):S489. x-wiley/crsRef/3261680
9. Van de Vlekkert J, Hoogendijk JE, De Haan RJ, Algra A, Van der Tweel I, Van der Pol WL, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscular Disorders 2010;20(6):382-9. [PUBMED: 20423755]x-wiley/crsRef/3261682
10. Vencovský J, Jarosová K, Machácek S, Studýnková J, Kafková J, Bartůnková J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scandinavian Journal of Rheumatology 2000;29(2):95-102. [PUBMED: 10777122]x-wiley/crsRef/3261684
11. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis and Rheumatism 1998;41(3):392-9. x-wiley/crsRef/3261686
12. Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow up. Arthritis and Rheumatism 1981;24(1):45-8. x-wiley/crsRef/3261688
13. Chung Y, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Ståhl-Hallengren C, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 2007;57:694-702. x-wiley/crsRef/3261690
14. Donov G, Kartasheva V, Fomenko T. Experimental use of plasmapheresis in juvenile dermatomyositis therapy. Clinical & Experimental Rheumatology 1995;13 Suppl 13:561. x-wiley/crsRef/3261692
15. Fries JF, Sharp GC, McDevitt HO, Holman HR. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis and Rheumatism 1973;16(2):154-62. [PUBMED: 4716431]x-wiley/crsRef/3261694
16. ISRCTN40085050. Second line agents in myositis. http://www.controlled-trials.com/ISRCTN40085050 (accessed 16 March 2012). x-wiley/crsRef/3261696
17. NCT00001261. Intravenousimmunoglobulin (IVIg) for the treatment of inflammatory myopathies. http://clinicaltrials.gov/ct2/show/NCT00001261 (accessed 16 March 2012). x-wiley/crsRef/3261698
18. NCT00035958. Understanding the pathogenesis and treatment of childhood onset dermatomyositis. http://clinicaltrials.gov/ct2/show/NCT00035958 (accessed 16 March 2012). x-wiley/crsRef/3261700
19. NCT00106184. Rituximab for the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM). http://clinicaltrials.gov/ct2/show/NCT00106184 (accessed 16 March 2012). x-wiley/crsRef/3261702
20. NCT00323960. Five-year actively controlled clinical trial in new onset juvenile dermatomyositis (PRINTOJDMTR). http://clinicaltrials.gov/ct2/show/NCT00323960 (accessed 16 March 2012). x-wiley/crsRef/3261704
21. NCT00335985. Efficacy and safety study of GB-0998 for treatment of steroid-resistant polymyositis and dermatomyositis (PM/DM). http://clinicaltrials.gov/ct2/show/NCT00335985 (accessed 16 March 2012). x-wiley/crsRef/3261706
22. NCT00533091. A study to evaluate safety of multi-dose MEDI-545 in adult patients with dermatomyositis or polymyositis. http://clinicaltrials.gov/ct2/show/NCT00533091 (accessed 16 March 2012). x-wiley/crsRef/3261708
23. NCT00651040. Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (Prometheus). http://clinicaltrials.gov/ct2/show/NCT00651040 (accessed 16 March 2012). x-wiley/crsRef/3261710
24. NCT01148810. Efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis. http://clinicaltrials.gov/ct2/show/NCT01148810 (accessed 16 March 2012). x-wiley/crsRef/3261712
25. NCT01315938. Abatacept treatment in polymyositis and dermatomyositis (ARTEMIS). http://clinicaltrials.gov/ct2/show/NCT01315938 (accessed 16 March 2012). x-wiley/crsRef/3261714
26. Ahlstrom G, Gunnarsson LG, Leissner P, Sjoden PO. Epidemiology of neuromuscular diseases, including the postpolio sequelae, in a Swedish county. Neuroepidemiology 1993;12(5):262-9.
27. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). New England Journal of Medicine 1975;292(7):344-7.
28. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). New England Journal of Medicine 1975;292(8):403-7.
29. Carpenter JR, Bunch TW, Engel AG, O'Brien PC. Survival in polymyositis: corticosteroids and risk factors. Journal of Rheumatology 1977;4(2):207-14.
30. Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology 2002;41(1):7-13.
31. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. New England Journal of Medicine 1991;325(21):1487-98.
32. Dalakas MC. Progress in inflammatory myopathies: good but not good enough. Journal of Neurology, Neurosurgery and Psychiatry 2001;70(5):569-73.
33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscular Disorders 2004;14(5):337-45.
35. Isenberg D A, Allen E, Farewell V, Ehrenstein MR, Hanna M G, Lundberg IE, et al for the International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43(1):49-54.
36. Joffe MM, Love L, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy. American Journal of Medicine 1993;94(4):379-87.
37. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis and Rheumatism 2005;52(9):2607-15.
38. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
39. Riddoch D, Morgan-Hughes JA. Prognosis in adult polymyositis. Journal of the Neurological Sciences 1975;26(1):71-80.
40. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis and Rheumatism 2004;50(7):2281-90.
41. Van de Vlekkert J, Tjin-A-Ton ML, Hoogendijk JE. Quality of myositis case reports open to improvement. Arthritis and Rheumatism 2004;51(1):148-50.
42. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604-7.
43. Choy EHS, Winer J, Lecky B, Hoogendik J. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003643]
44. Choy EHS, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD003643.pub2]
45. Choy EHS, Hoogendijk JE, Lecky B, Winer JB, Gordon P. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD003643.pub3]